ANTX: AN2 Bio Growth-Adjusted Market Cap to Net Income

Symbol and logo of brand AN2 Bio (ANTX)

The development of new antibiotics in the US coincides with a period of R&D portfolio restructuring and management adaptation for AN2 Therapeutics, Inc. (ANTX). The weighted PEG ratio on the GURU.Markets dynamic chart reflects the current valuation, where the 0.00 mark indicates the asset's market value level. Looking ahead, AN2 Therapeutics, Inc. (ANTX) aims to expand its range of drugs against rare pulmonary infections and commercialize epetraronal.

ANTX (an2therapeutics.com) PEG Multiple history from 04/28/2023 to 11/16/2026

Analytical breakdowns for AN2 Therapeutics Inc (ANTX)

Summary company analytics:AN2 Bio
Mass-produced product of AN2 Therapeutics

AN2 Therapeutics, Inc. (ANTX) develops antibiotics for the treatment of pulmonary infections, leveraging R&D patent protection. By analyzing the normalized PEG ratio, an investor compares the company's market value with its earnings growth. This metric divides the P/E ratio by the revenue growth rate, revealing any disproportion between price and expansion. A value below one signals an undervaluation of the scalable business's potential, allowing for the efficient identification of undervalued assets with high leverage.